Abstract | BACKGROUND: METHODS: Newborns of both HBsAg- and HBeAg-positive carrier mothers received HBIG within 48 h of birth and at 2 months of age. Subsequently, three doses of recombinant HB vaccine were given at 2, 3, and 5 months of age. Outcome was compared between the following two groups: infants who completed the vaccination program, even if they were HBsAg positive at 1 month of age (n = 15), and infants who did not (n = 51). RESULTS: Seroconversion from HBeAg to anti-HBe antibody (HBeAb) before 3 years of age was observed in five children (33%) who completed the vaccination program and in two (4%) who did not (P = 0.005). In 2/5 children who completed the vaccination program and achieved HBeAb seroconversion, seroconversion from HBsAg to anti-HBs antibody was also noted. CONCLUSION: This specific vaccination program for children with prenatal HBV infection has the potential to alter immune tolerance to HBV.
|
Authors | Kentaro Iwasawa, Ayano Inui, Tomoyuki Tsunoda, Takeo Kondo, Manari Kawamoto, Tsuyoshi Sogo, Haruki Komatsu, Tomoo Fujisawa |
Journal | Pediatrics international : official journal of the Japan Pediatric Society
(Pediatr Int)
Vol. 57
Issue 3
Pg. 401-5
(Jun 2015)
ISSN: 1442-200X [Electronic] Australia |
PMID | 25331640
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2014 Japan Pediatric Society. |
Chemical References |
- DNA, Viral
- Hepatitis B Antibodies
- Hepatitis B Vaccines
- Immunoglobulins
- hepatitis B hyperimmune globulin
|
Topics |
- DNA, Viral
(analysis)
- Female
- Follow-Up Studies
- Hepatitis B
(therapy, virology)
- Hepatitis B Antibodies
(analysis)
- Hepatitis B Vaccines
(administration & dosage, genetics, immunology)
- Hepatitis B virus
(immunology)
- Humans
- Immunization, Passive
- Immunoglobulins
(administration & dosage)
- Incidence
- Infant
- Japan
(epidemiology)
- Male
- Retrospective Studies
- Treatment Outcome
- Uterine Diseases
(drug therapy, epidemiology, virology)
|